

DAFTAR PUSTAKA

- ABDUL NASIR, N. A., AGARWAL, R., SHEIKH ABDUL KADIR, S. H., VASUDEVAN, S., TRIPATHY, M., IEZHITSA, I., MOHAMMAD DAHER, A., IBRAHIM, M. I. & MOHD ISMAIL, N. 2017. Reduction of oxidative-nitrosative stress underlies anticataract effect of topically applied tocotrienol in streptozotocin-induced diabetic rats. *PLOS ONE*, 12, e0174542.
- AL-ASADI, S. Z., NAZAR, W. & MOAYEED, S. 2020. Interleukin in Aqueous Humor of Phacoemulsification Surgery. *Iraqi Natl J Med*, 2, 95-100.
- ARELLANO ARIAS, E. S., ROBLES-CONTRERAS, A. & MEDINA-PEREZ, A. B. 2017. Role of TNF alpha in senile, diabetic and traumatic cataract. *Investigative Ophthalmology & Visual Science*, 58, 3181-3181.
- BAZZONI, F. & BEUTLER, B. 1996. The tumor necrosis factor ligand and receptor families. *N Engl J Med*, 334, 1717-25.
- BELLINGAN, G. J., CALDWELL, H., HOWIE, S. E., DRANSFIELD, I. & HASLETT, C. 1996. In vivo fate of the inflammatory macrophage during the resolution of inflammation: inflammatory macrophages do not die locally, but emigrate to the draining lymph nodes. *J Immunol*, 157, 2577-85.
- BERTHOUD, V. M. & BEYER, E. C. 2009. Oxidative stress, lens gap junctions, and cataracts. *Antioxid Redox Signal*, 11, 339-53.
- BESSA, A. S., RAGAB, A. M., NASSRA, R. A., PIÑERO, D. P. & SHAHEEN, M. S. 2018. Expression levels of aldose reductase enzyme, vascular endothelial growth factor, and intercellular adhesion molecule-1 in the anterior lens capsule of diabetic cataract patients. *J Cataract Refract Surg*, 44, 1431-1435.
- BOZKURT, E., ÇAKIR, B., ÇELİK, E., DOĞAN, E., UÇAK, T. & ALAGÖZ, G. 2019. Correlation of the aqueous humor total antioxidant capacity, total oxidant status, and levels of IL-6 and VEGF with diabetic retinopathy status. *Arquivos Brasileiros de Oftalmologia*, 82.
- BRENNER, D., BLASER, H. & MAK, T. W. 2015. Regulation of tumour necrosis factor signalling: live or let die. *Nat Rev Immunol*, 15, 362-74.
- CALLE, M. C. & FERNANDEZ, M. L. 2012. Inflammation and type 2 diabetes. *Diabetes Metab*, 38, 183-91.
- CHEN, Y.-Y., WU, T.-T., HO, C.-Y., YEH, T.-C., SUN, G.-C., TSENG, C.-J. & CHENG, P.-W. 2022. Blocking of SGLT2 to Eliminate NADPH-Induced Oxidative Stress in Lenses of Animals with Fructose-Induced Diabetes Mellitus. *International Journal of Molecular Sciences*, 23, 7142.
- CHEN, Y., HAO, W., WANG, M., WU, F., LONG, D., LI, T., ZHANG, Y., WANG, X., LU, B., DU, C. & WU, Q. 2023. Cytokine status and significant increase of IL-6 and sIL-6R in the aqueous humor of diabetic cataract patients revealed by quantitative multiplexed assays. *J Int Med Res*, 51, 3000605231175765.
- CHEUNG, C. M., VANIA, M., ANG, M., CHEE, S. P. & LI, J. 2012. Comparison of aqueous humor cytokine and chemokine levels in diabetic patients with and without retinopathy. *Mol Vis*, 18, 830-7.

- CHUNG, S. S. M., HO, E. C. M., LAM, K. S. L. & CHUNG, S. K. 2003. Contribution of Polyol Pathway to Diabetes-Induced Oxidative Stress. *Journal of the American Society of Nephrology*, 14, S233-S236.
- DAHLAN, M. S. 2013. Besar Sampel dan Cara Pengambilan Sampel (edisi 3). *Jakarta Salemba Medika*.
- DANYSH, B. P. & DUNCAN, M. K. 2009. The lens capsule. *Exp Eye Res*, 88, 151-64.
- DE IONGH, R. U., WEDERELL, E., LOVICU, F. J. & MCAVOY, J. W. 2005. Transforming Growth Factor- β -Induced Epithelial-Mesenchymal Transition in the Lens: A Model for Cataract Formation. *Cells Tissues Organs*, 179, 43-55.
- DELAMERE, N. A. & TAMIYA, S. 2004. Expression, regulation and function of Na,K-ATPase in the lens. *Prog Retin Eye Res*, 23, 593-615.
- DESGEORGES, A., GABAY, C., SILACCI, P., NOVICK, D., ROUX-LOMBARD, P., GRAU, G., DAYER, J. M., VISCHER, T. & GUERNE, P. A. 1997. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. *J Rheumatol*, 24, 1510-6.
- DOLAR-SZCZASNY, J., DRAB, A. & REJDAK, R. 2024. Biochemical Changes in Anterior Chamber of the Eye in Diabetic Patients—A Review. *Journal of Clinical Medicine*, 13, 2581.
- EBIHARA, N., MATSUDA, A., NAKAMURA, S., MATSUDA, H. & MURAKAMI, A. 2011. Role of the IL-6 classic- and trans-signaling pathways in corneal sterile inflammation and wound healing. *Invest Ophthalmol Vis Sci*, 52, 8549-57.
- EDERER, F., HILLER, R. & TAYLOR, H. R. 1981. Senile Lens Changes and Diabetes in two Population Studies. *American Journal of Ophthalmology*, 91, 381-395.
- EHLERS, S. 2003. Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF. *Ann Rheum Dis*, 62 Suppl 2, ii37-42.
- ETDRS 1991. Grading Diabetic Retinopathy from Stereoscopic Color Fundus Photographs—An Extension of the Modified Airlie House Classification: ETDRS Report Number 10. *Ophthalmology*, 98, 786-806.
- FEDERATION, I. D. 2021. *IDF Diabetes Atlas 10th Edition*, IDF.
- FENG, S., YU, H., YU, Y., GENG, Y., LI, D., YANG, C., LV, Q., LU, L., LIU, T., LI, G. & YUAN, L. 2018. Levels of Inflammatory Cytokines IL-1 β , IL-6, IL-8, IL-17A, and TNF- α in Aqueous Humour of Patients with Diabetic Retinopathy. *J Diabetes Res*, 2018, 8546423.
- FISCHER, R. & MAIER, O. 2015. Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. *Oxid Med Cell Longev*, 2015, 610813.
- FRIEDRICH, M. G. & TRUSCOTT, R. J. 2009. Membrane association of proteins in the aging human lens: profound changes take place in the fifth decade of life. *Invest Ophthalmol Vis Sci*, 50, 4786-93.
- FULGÊNCIO CUNHA, A. A., BOSCO, A. A., VELOSO, C. A., VOLPE, C. M. O., CHAVES, M. M. & NOGUEIRA-MACHADO, J. A. 2013. Suppressive effect of aqueous humor from person with Type 2 diabetes with or without retinopathy on reactive oxygen species generation. *Diabetes Research and Clinical Practice*, 100, 69-73.
- FUNATSU, H., YAMASHITA, H., NOMA, H., MIMURA, T., NAKAMURA, S., SAKATA, K. & HORI, S. 2005. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. *Graefes Archive for Clinical and Experimental Ophthalmology*, 243, 3-8.

- FUNATSU, H., YAMASHITA, H., NOMA, H., MIMURA, T., YAMASHITA, T. & HORI, S. 2002. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. *American Journal of Ophthalmology*, 133, 70-77.
- GABAY, C. 2006. Interleukin-6 and chronic inflammation. *Arthritis Res Ther*, 8 Suppl 2, S3.
- GRELL, M., DOUNI, E., WAJANT, H., LÖHDEN, M., CLAUSS, M., MAXEINER, B., GEORGOPOULOS, S., LESSLAUER, W., KOLLIAS, G., PFIZENMAIER, K. & SCHEURICH, P. 1995. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. *Cell*, 83, 793-802.
- GUSTAVSSON, C., AGARDH, C. D. & AGARDH, E. 2013. Profile of intraocular tumour necrosis factor- α and interleukin-6 in diabetic subjects with different degrees of diabetic retinopathy. *Acta Ophthalmol*, 91, 445-52.
- HARDING, A. H., DAY, N. E., KHAW, K. T., BINGHAM, S., LUBEN, R., WELSH, A. & WAREHAM, N. J. 2004. Dietary fat and the risk of clinical type 2 diabetes: the European prospective investigation of Cancer-Norfolk study. *Am J Epidemiol*, 159, 73-82.
- HARDING, J. J., EGERTON, M., VAN HEYNINGEN, R. & HARDING, R. S. 1993. Diabetes, glaucoma, sex, and cataract: analysis of combined data from two case control studies. *Br J Ophthalmol*, 77, 2-6.
- HAROON, H. B., PERUMALSAMY, V., NAIR, G., ANAND, D. K., KOLLI, R., MONICHEN, J. & PRABHA, K. 2021. Repression of Polyol Pathway Activity by Hemidesmus indicus var. pubescens R.Br. Linn Root Extract, an Aldose Reductase Inhibitor: An In Silico and Ex Vivo Study. *Nat Prod Bioprospect*, 11, 315-324.
- HODGE, D. R., HURT, E. M. & FARRAR, W. L. 2005. The role of IL-6 and STAT3 in inflammation and cancer. *Eur J Cancer*, 41, 2502-12.
- HOEKZEMA, R., VERHAGEN, C., VAN HAREN, M. & KIJLSTRA, A. 1992. Endotoxin-induced uveitis in the rat. The significance of intraocular interleukin-6. *Invest Ophthalmol Vis Sci*, 33, 532-9.
- HONG, S. B., LEE, K. W., HANDA, J. T. & JOO, C. K. 2000. Effect of advanced glycation end products on lens epithelial cells in vitro. *Biochem Biophys Res Commun*, 275, 53-9.
- HOVLAND, P. G. 2020. Diabetic Retinopathy Severity and Cataract Surgery: When Less Is More. *Ophthalmol Retina*, 4, 349-350.
- HSU, H., SHU, H. B., PAN, M. G. & GOEDEL, D. V. 1996. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. *Cell*, 84, 299-308.
- HU, X., LI, J., FU, M., ZHAO, X. & WANG, W. 2021. The JAK/STAT signaling pathway: from bench to clinic. *Signal Transduction and Targeted Therapy*, 6, 402.
- HUANG, H., GANDHI, J. K., ZHONG, X., WEI, Y., GONG, J., DUH, E. J. & VINOES, S. A. 2011. TNF α is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. *Invest Ophthalmol Vis Sci*, 52, 1336-44.
- HURST, S. M., WILKINSON, T. S., MCLOUGHLIN, R. M., JONES, S., HORIUCHI, S., YAMAMOTO, N., ROSE-JOHN, S., FULLER, G. M., TOPLEY, N. & JONES, S. A. 2001. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. *Immunity*, 14, 705-14.

- JANG, D. I., LEE, A. H., SHIN, H. Y., SONG, H. R., PARK, J. H., KANG, T. B., LEE, S. R. & YANG, S. H. 2021. The Role of Tumor Necrosis Factor Alpha (TNF- α) in Autoimmune Disease and Current TNF- α Inhibitors in Therapeutics. *Int J Mol Sci*, 22.
- JIN, Z., ZHANG, Q., LIU, K., WANG, S., YAN, Y., ZHANG, B. & ZHAO, L. 2024. The association between interleukin family and diabetes mellitus and its complications: An overview of systematic reviews and meta-analyses. *Diabetes Research and Clinical Practice*, 210.
- JOBLING, A. I. & AUGUSTEYN, R. C. 2002. What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. *Clin Exp Optom*, 85, 61-75.
- JONES, S. A. 2005. Directing transition from innate to acquired immunity: defining a role for IL-6. *J Immunol*, 175, 3463-8.
- JONES, S. A., RICHARDS, P. J., SCHELLER, J. & ROSE-JOHN, S. 2005. IL-6 transsignaling: the in vivo consequences. *J Interferon Cytokine Res*, 25, 241-53.
- KALLIOLIAS, G. D. & IVASHKIV, L. B. 2016. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. *Nat Rev Rheumatol*, 12, 49-62.
- KALLURI, R. & NEILSON, E. G. 2003. Epithelial-mesenchymal transition and its implications for fibrosis. *The Journal of Clinical Investigation*, 112, 1776-1784.
- KAPLANSKI, G., MARIN, V., MONTERO-JULIAN, F., MANTOVANI, A. & FARNARIER, C. 2003. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. *Trends Immunol*, 24, 25-9.
- KERNER, W. & BRÜCKEL, J. 2014. Definition, classification and diagnosis of diabetes mellitus. *Exp Clin Endocrinol Diabetes*, 122, 384-6.
- KIZILTOPRAK, H., TEKIN, K., INANC, M. & GOKER, Y. S. 2019. Cataract in diabetes mellitus. *World J Diabetes*, 10, 140-153.
- KLAASSEN, I., VAN NOORDEN, C. J. F. & SCHLINGEMANN, R. O. 2013. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. *Progress in Retinal and Eye Research*, 34, 19-48.
- KLEIN, B. E., KLEIN, R. & MOSS, S. E. 1985. Prevalence of cataracts in a population-based study of persons with diabetes mellitus. *Ophthalmology*, 92, 1191-6.
- KORLIMBINIS, A., BERRY, Y., THIBAUT, D., SCHEY, K. L. & TRUSCOTT, R. J. 2009. Protein aging: truncation of aquaporin 0 in human lens regions is a continuous age-dependent process. *Exp Eye Res*, 88, 966-73.
- KOSKELA, U. E., KUUSISTO, S. M., NISSINEN, A. E., SAVOLAINEN, M. J. & LIINAMAA, M. J. 2012. High Vitreous Concentration of IL-6 and IL-8, but Not of Adhesion Molecules in Relation to Plasma Concentrations in Proliferative Diabetic Retinopathy. *Ophthalmic Research*, 49, 108-114.
- KUMAMOTO, Y., TAKAMURA, Y., KUBO, E., TSUZUKI, S. & AKAGI, Y. 2007. Epithelial cell density in cataractous lenses of patients with diabetes: Association with erythrocyte aldose reductase. *Experimental Eye Research*, 85, 393-399.
- KUMAR, C. U., SURYAVANSHI, U., SONTAKE, V., REDDY, P. Y., SANKHALA, R. S., SWAMY, M. J. & REDDY, G. B. 2022. Effect of Sorbitol on Alpha-Crystallin Structure and Function. *Biochemistry (Moscow)*, 87, 131-140.
- LAGATHU, C., BASTARD, J. P., AUCLAIR, M., MAACHI, M., CAPEAU, J. & CARON, M. 2003. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. *Biochem Biophys Res Commun*, 311, 372-9.

- LI, Q. & VERMA, I. M. 2002. NF-kappaB regulation in the immune system. *Nat Rev Immunol*, 2, 725-34.
- LIM, S. A., JOO, C. K., KIM, M. S. & CHUNG, S. K. 2014. Expression of p53 and caspase-8 in lens epithelial cells of diabetic cataract. *J Cataract Refract Surg*, 40, 1102-8.
- LITTLE, B. C., SMITH, J. H. & PACKER, M. 2006. Little capsulorhexis tear-out rescue. *J Cataract Refract Surg*, 32, 1420-2.
- LIU, H., SMITH, A., BALL, S., BAO, Y., BOWATER, R., WANG, N. & WORMSTONE, I. 2017. Sulforaphane promotes ER stress, autophagy, and cell death: implications for cataract surgery. *Journal of molecular medicine (Berlin, Germany)*, 95.
- LIU, Q. 2021. Continuous Curvilinear Capsulorhexis. In: XIAOGANG, W. (ed.) *Current Cataract Surgical Techniques*. Rijeka: IntechOpen.
- M. JOUSSEN, A., POULAKI, V., MITSIADES, N., KIRCHHOF, B., KOIZUMI, K., DÖHMEN, S. & P. ADAMIS, A. 2002. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF- α suppression. *The FASEB Journal*, 16, 438-440.
- MARIN, V., MONTERO-JULIAN, F. A., GRÈS, S., BOULAY, V., BONGRAND, P., FARNARIER, C. & KAPLANSKI, G. 2001. The IL-6-soluble IL-6R α autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin. *J Immunol*, 167, 3435-42.
- MESQUIDA, M., DRAWNEL, F., LAIT, P. J., COPLAND, D. A., STIMPSON, M. L., LLORENÇ, V., SAINZ DE LA MAZA, M., ADAN, A., WIDMER, G., STRASSBURGER, P., FAUSER, S., DICK, A. D., LEE, R. W. J. & MOLINS, B. 2019. Modelling Macular Edema: The Effect of IL-6 and IL-6R Blockade on Human Blood-Retinal Barrier Integrity In Vitro. *Transl Vis Sci Technol*, 8, 32.
- MOCAN, M. C., KADAYIFCILAR, S. & ELDEM, B. 2006. Elevated intravitreal interleukin-6 levels in patients with proliferative diabetic retinopathy. *Canadian Journal of Ophthalmology*, 41, 747-752.
- MOHAMMADPOUR, M., ERFANIAN, R. & KARIMI, N. 2012. Capsulorhexis: Pearls and pitfalls. *Saudi J Ophthalmol*, 26, 33-40.
- MOLLER, D. E. 2000. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. *Trends Endocrinol Metab*, 11, 212-7.
- MOUSTARDAS, P., ABERDAM, D. & LAGALI, N. 2023. MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges. *Cells*, 12, 617.
- MRUGACZ, M., PONY-URAM, M., BRYL, A. & ZORENA, K. 2023. Current Approach to the Pathogenesis of Diabetic Cataracts. *Int J Mol Sci*, 24.
- NAKA, T., NARAZAKI, M., HIRATA, M., MATSUMOTO, T., MINAMOTO, S., AONO, A., NISHIMOTO, N., KAJITA, T., TAGA, T., YOSHIZAKI, K., AKIRA, S. & KISHIMOTO, T. 1997. Structure and function of a new STAT-induced STAT inhibitor. *Nature*, 387, 924-9.
- NISHI, O., NISHI, K. & OHMOTO, Y. 1996. Synthesis of interleukin-1, interleukin-6, and basic fibroblast growth factor by human cataract lens epithelial cells. *Journal of Cataract & Refractive Surgery*, 22, 852-858.
- OBADĂ, O., PANTALON, A. D., RUSU-ZOTA, G., HĂISAN, A., LUPUȘORU, S. I., CONSTANTINESCU, D. & CHISELIȚĂ, D. 2022. Aqueous Humor Cytokines in Non-Proliferative Diabetic Retinopathy. *Medicina (Kaunas)*, 58.
- OISHI, N., MORIKUBO, S., TAKAMURA, Y., KUBO, E., TSUZUKI, S., TANIMOTO, T. & AKAGI, Y. 2006. Correlation between Adult Diabetic Cataracts and Red Blood Cell Aldose Reductase Levels. *Investigative Ophthalmology & Visual Science*, 47, 2061-2064.

- OKDAHL, T., WEGEBERG, A. M., POCIOT, F., BROCK, B., STØRLING, J. & BROCK, C. 2022. Low-grade inflammation in type 2 diabetes: a cross-sectional study from a Danish diabetes outpatient clinic. *BMJ Open*, 12, e062188.
- OLAFSDOTTIR, E., ANDERSSON, D. K. G. & STEFÁNSSON, E. 2012. The prevalence of cataract in a population with and without type 2 diabetes mellitus. *Acta Ophthalmologica*, 90, 334-340.
- OZOUGWU, J., OBIMBA, K. C., BELONWU, C. D. & UNAKALAMBA, C. B. 2013. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. *Academic Journals*, 4, 46-57.
- PASPARAKIS, M. & VANDENABEELE, P. 2015. Necroptosis and its role in inflammation. *Nature*, 517, 311-320.
- PROBERT, L. 2015. TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects. *Neuroscience*, 302, 2-22.
- RANDOLPH, G. J., BEAULIEU, S., LEBECQUE, S., STEINMAN, R. M. & MULLER, W. A. 1998. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. *Science*, 282, 480-3.
- REMINGTON, L. A. 2012. *Clinical Anatomy and Physiology of the Visual System*, Missouri, Elsevier.
- RICHTER, G. M., TORRES, M., CHOUDHURY, F., AZEN, S. P. & VARMA, R. 2012. Risk Factors for Cortical, Nuclear, Posterior Subcapsular, and Mixed Lens Opacities: The Los Angeles Latino Eye Study. *Ophthalmology*, 119, 547-554.
- ROMANO, M., SIRONI, M., TONIATTI, C., POLENTARUTTI, N., FRUSCELLA, P., GHEZZI, P., FAGGIONI, R., LUINI, W., VAN HINSBERGH, V., SOZZANI, S., BUSSOLINO, F., POLI, V., CILIBERTO, G. & MANTOVANI, A. 1997. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. *Immunity*, 6, 315-25.
- SANTEE, S. M. & OWEN-SCHAUB, L. B. 1996. Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization. *J Biol Chem*, 271, 21151-9.
- SAWADA, H., FUKUCHI, T., TANAKA, T. & ABE, H. 2010. Tumor Necrosis Factor- α Concentrations in the Aqueous Humor of Patients with Glaucoma. *Investigative Ophthalmology & Visual Science*, 51, 903-906.
- SAYIN, N., KARA, N. & PEKEL, G. 2015. Ocular complications of diabetes mellitus. *World J Diabetes*, 6, 92-108.
- SCHALL, T. J., LEWIS, M., KOLLER, K. J., LEE, A., RICE, G. C., WONG, G. H., GATANAGA, T., GRANGER, G. A., LENTZ, R., RAAB, H. & ET AL. 1990. Molecular cloning and expression of a receptor for human tumor necrosis factor. *Cell*, 61, 361-70.
- SCHELLER, J., CHALARIS, A., SCHMIDT-ARRAS, D. & ROSE-JOHN, S. 2011. The pro- and anti-inflammatory properties of the cytokine interleukin-6. *Biochim Biophys Acta*, 1813, 878-88.
- SEVIN, G., KERRY, Z., SOZER, N. & OZSARLAK-SOZER, G. 2021. Taurine supplementation protects lens against glutathione depletion. *Eur Rev Med Pharmacol Sci*, 25, 4520-4526.
- SHARMA, S. 2021. Interleukin-6 Trans-signaling: A Pathway With Therapeutic Potential for Diabetic Retinopathy. *Frontiers in Physiology*, 12.

- SHIRAI, K., TANAKA, S.-I., LOVICU, F. J. & SAIKA, S. 2018. The murine lens: A model to investigate in vivo epithelial–mesenchymal transition. *Developmental Dynamics*, 247, 340-345.
- SILVA, L., NETO, A., MAIA, S., GUIMARÃES, C., QUIDUTE, I., CARVALHO, A. D. A., JÚNIOR, S. & LEÃO, J. 2019. The Role of TNF- α as a Proinflammatory Cytokine in Pathological Processes. *The Open Dentistry Journal*, 13, 332-338.
- SINGH, R., ALPERN, L., JAFFE, G. J., LEHMANN, R. P., LIM, J., REISER, H. J., SALL, K., WALTERS, T. & SAGER, D. 2012. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. *Clin Ophthalmol*, 6, 1259-69.
- SPRAGUE, A. H. & KHALIL, R. A. 2009. Inflammatory cytokines in vascular dysfunction and vascular disease. *Biochem Pharmacol*, 78, 539-52.
- SRINIVASAN, S., RAMAN, R., SWAMINATHAN, G., GANESAN, S., KULOTHUNGAN, V. & SHARMA, T. 2017. Incidence, Progression, and Risk Factors for Cataract in Type 2 Diabetes. *Investigative Ophthalmology & Visual Science*, 58, 5921-5929.
- STANGA, P. E., BOYD, S. R. & HAMILTON, A. M. 1999. Ocular manifestations of diabetes mellitus. *Curr Opin Ophthalmol*, 10, 483-9.
- SUGITA, S., TAKASE, H., TAGUCHI, C. & MOCHIZUKI, M. 2007. The Role of Soluble TNF Receptors for TNF- α in Uveitis. *Investigative Ophthalmology & Visual Science*, 48, 3246-3252.
- SWEENEY, M. H. & TRUSCOTT, R. J. 1998. An impediment to glutathione diffusion in older normal human lenses: a possible precondition for nuclear cataract. *Exp Eye Res*, 67, 587-95.
- TABIN, G., CHEN, M. & ESPANDAR, L. 2008. Cataract surgery for the developing world. *Curr Opin Ophthalmol*, 19, 55-9.
- TAKAMURA, Y., SUGIMOTO, Y., KUBO, E., TAKAHASHI, Y. & AKAGI, Y. 2001. Immunohistochemical study of apoptosis of lens epithelial cells in human and diabetic rat cataracts. *Jpn J Ophthalmol*, 45, 559-63.
- TAKEMOTO, L. & SORENSEN, C. M. 2008. Protein-protein interactions and lens transparency. *Exp Eye Res*, 87, 496-501.
- TANABE, K., MATSUSHIMA-NISHIWAKI, R., YAMAGUCHI, S., IIDA, H., DOHI, S. & KOZAWA, O. 2010. Mechanisms of tumor necrosis factor- α -induced interleukin-6 synthesis in glioma cells. *J Neuroinflammation*, 7, 16.
- TROKEL, S. 1962. The Physical Basis for Transparency of the Crystalline Lens. *Investigative Ophthalmology & Visual Science*, 1, 493-501.
- TRUSCOTT, R. J. 2000. Age-related nuclear cataract: a lens transport problem. *Ophthalmic Res*, 32, 185-94.
- TRUSCOTT, R. J. 2009. Presbyopia. Emerging from a blur towards an understanding of the molecular basis for this most common eye condition. *Exp Eye Res*, 88, 241-7.
- TURAN, M. & TURAN, G. 2022. Immunoreactivity of ICAM-1, MMP-2, and Nesfatin-1 in lens epithelial cells of patients with diabetes mellitus with or without diabetic retinopathy. *Eur J Ophthalmol*, 32, 255-262.
- VALLE, M. L., DWORSHAK, J., SHARMA, A., IBRAHIM, A. S., AL-SHABRAWAY, M. & SHARMA, S. 2019. Inhibition of interleukin-6 trans-signaling prevents inflammation and endothelial barrier disruption in retinal endothelial cells. *Exp Eye Res*, 178, 27-36.
- VAVVAS, D., AZAR, N. F. & AZAR, D. T. 2002. Mechanisms of disease: cataracts. *Ophthalmol Clin North Am*, 15, 49-60.

- WIELDERS, L. H. P., SCHOUTEN, J. S. A. G., WINKENS, B., VAN DEN BIGGELAAR, F. J. H. M., VELDHUIZEN, C. A., MURTA, J. C. N., GOSLINGS, W. R. O., KOHNEN, T., TASSIGNON, M.-J., JOOSSE, M. V., HENRY, Y. P., NAGY, Z. Z., RULO, A. H. F., FINDL, O., AMON, M., NUIJTS, R. M. M. A. & GROUP, O. B. O. T. E. P. S. 2018. Randomized controlled European multicenter trial on the prevention of cystoid macular edema after cataract surgery in diabetics: ESCRS PREMED Study Report 2. *Journal of Cataract & Refractive Surgery*, 44, 836-847.
- XIE, Q., XUE, L., CAO, X., HUANG, L. & SONG, Y. 2023. Apoptosis of Lens Epithelial Cells and Expression of NLRP3-related Proteins in Patients with Diabetes and Cataract. *Ocular Immunology and Inflammation*, 31, 1103-1110.
- XU, H., LIU, J., NIU, M., SONG, S., WEI, L., CHEN, G., DING, Y., WANG, Y., SU, Z. & WANG, H. 2021. Soluble IL-6R-mediated IL-6 trans-signaling activation contributes to the pathological development of psoriasis. *J Mol Med (Berl)*, 99, 1009-1020.
- YAMASHIRO, S., KAMOHARA, H. & YOSHIMURA, T. 1999. MCP-1 is selectively expressed in the late phase by cytokine-stimulated human neutrophils: TNF-alpha plays a role in maximal MCP-1 mRNA expression. *J Leukoc Biol*, 65, 671-9.
- YANG, Q., ZHAO, G. Q., LI, Q. & LIU, X. P. 2006. Expression of nuclear factor-kappaB in traumatic cataract. *Chin J Traumatol*, 9, 86-90.
- YI, Q. Y., WANG, Y. Y., CHEN, L. S., LI, W. D., SHEN, Y., JIN, Y., YANG, J., WANG, Y., YUAN, J. & CHENG, L. 2020. Implication of inflammatory cytokines in the aqueous humour for management of macular diseases. *Acta Ophthalmol*, 98, e309-e315.
- YOSHIDA, M., TAKEUCHI, M. & STREILEIN, J. W. 2000. Participation of pigment epithelium of iris and ciliary body in ocular immune privilege. 1. Inhibition of T-cell activation in vitro by direct cell-to-cell contact. *Invest Ophthalmol Vis Sci*, 41, 811-21.
- YUE, T., SHI, Y., LUO, S., WENG, J., WU, Y. & ZHENG, X. 2022. The role of inflammation in immune system of diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. *Front Immunol*, 13, 1055087.
- YUN, J. H., PARK, S. W., KIM, K. J., BAE, J. S., LEE, E. H., PAEK, S. H., KIM, S. U., YE, S., KIM, J. H. & CHO, C. H. 2017. Endothelial STAT3 Activation Increases Vascular Leakage Through Downregulating Tight Junction Proteins: Implications for Diabetic Retinopathy. *J Cell Physiol*, 232, 1123-1134.
- ZHANG, H., LIANG, L., HUANG, R., WU, P. & HE, L. 2020. Comparison of inflammatory cytokines levels in the aqueous humor with diabetic retinopathy. *Int Ophthalmol*, 40, 2763-2769.
- ZHANG, S. X., WANG, J. J., GAO, G., SHAO, C., MOTT, R. & MA, J. X. 2006. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. *Faseb j*, 20, 323-5.
- ZHOU, L., SUN, H., XU, J. & KANG, J. 2010. [Level of vascular endothelial growth factor and interleukin-6 in aqueous humor in diabetic retinopathy patients]. *Yan Ke Xue Bao*, 25, 26-30.
- ZHU, H. C., TAO, Y. & LI, Y. M. 2019. Correlations of insulin resistance and HbA1c with cytokines IGF-1, bFGF and IL-6 in the aqueous humor of patients with diabetic cataract. *Eur Rev Med Pharmacol Sci*, 23, 16-22.
- ZYCH, M., WOJNAR, W., KIELANOWSKA, M., FOLWARCZNA, J. & KACZMARCZYK-SEDLAK, I. 2020. Effect of Berberine on Glycation, Aldose Reductase Activity, and Oxidative Stress in the Lenses of Streptozotocin-Induced Diabetic Rats In Vivo-A Preliminary Study. *Int J Mol Sci*, 21.

Lampiran 1 : Rekomendasi Persetujuan Etik



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 189/UN4.6.4.5.31/ PP36/ 2024

Tanggal: 20 Maret 2024

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH24020084	No Sponsor	
Peneliti Utama	dr. Cindy Hartono	Sponsor	
Judul Peneliti	INTERLEUKIN-6 DAN TUMOR NECROSIS FACTOR-ALPHA PADA SEL EPITEL KAPSUL ANTERIOR LENSA DAN HUMOR AKUOS SEBAGAI MEDIATOR INFLAMASI PADA KATARAK DIABETIK		
No Versi Protokol	2	Tanggal Versi	15 Maret 2024
No Versi PSP	2	Tanggal Versi	15 Maret 2024
Tempat Penelitian	RS Universitas Hasanuddin Dan Klinik Mata JEC @ Orbita Makassar		
Jenis Review	☐ Exempted ☐ Expedited ☒ Fullboard Tanggal 28 Februari 2024	Masa Berlaku 20 Maret 2024 sampai 20 Maret 2025	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laport SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2 : Formulir Persetujuan

FORMULIR PERSETUJUAN SETELAH PENJELASAN

Saya yang bertanda tangan di bawah ini :

Nama :

Umur :tahun

Alamat :

Telepon/HP :

Menyatakan bersedia untuk berpartisipasi pada penelitian ini yang berjudul :

**“INTERLEUKIN-6 DAN TUMOR NECROSIS FACTOR-ALPHA PADA SEL EPITEL
KAPSUL ANTERIOR LENSE DAN HUMOR AKUOS SEBAGAI MEDIATOR
INFLAMASI PADA KATARAK DIABETIK”**

Setelah mendengar/membaca dan mengerti penjelasan yang diberikan mengenai tujuan dan manfaat yang akan didapatkan pada penelitian ini, khususnya bagi kemajuan ilmu kedokteran.

Makassar,

Responden/Wali

Saksi

(.....)

(.....)

Penanggung jawab penelitian :

Nama : dr. Cindy Hartono

Alamat : Kompleks IDI G9/8

Telp. : 082149401646

Penanggung jawab medik :

Nama : dr. Muhammad Abrar Ismail, Sp.M(K), M.Kes

Alamat : Jl. Sultan Alauddin no 84A

Telp. : 081343884693

Lampiran 3 : Formulir Penelitian

INTERLEUKIN-6 DAN TUMOR NECROSIS FACTOR-ALPHA PADA SEL EPITEL KAPSUL ANTERIOR LENSA DAN HUMOR AKUOS SEBAGAI MEDIATOR INFLAMASI PADA KATARAK DIABETIK

Nama pasien: _____ No Rekam Medis : _____

Tanggal lahir: ____/____/____

Jenis kelamin : Laki-laki ☐ Perempuan ☐

Alamat tinggal asal :

Pasien dari rumah sakit :

a. RS PENDIDIKAN UNHAS : []

b. KLINIK JEC @ORBITA : []

Pasien rujukan , asal rumah sakit :

Riwayat DM* : Ya / Tidak

Durasi menderita DM : _____

Riwayat pengobatan DM sebelumnya : Ya/Tidak , jenis pengobatan _____

Gula darah sewaktu terakhir : _____ mg/dL

HbA1c terakhir : _____ %

PEMERIKSAAN OFTALMOLOGI

Visus Oculus dextra :

Visus Oculus sinistra :

Tekanan Intra Okular :

PEMERIKSAAN SLITLAMP

OD	SLIT LAMP	OS
	PALPEBRA	
	KONJUNGTIVA / SKLERA	
	KORNEA	

	BMD	
	IRIS	
	PUPIL	
	LENSA	
	GRADING KATARAK BERDASARKAN BURRATO	

Retinopati diabetik : Ya / Tidak , bila Ya, Grading retinopati diabetik : _____

Diagnosis kerja :

Pemeriksaan IHC kapsul lensa untuk ekspresi IL-6 dan TNF- α

- Ekspresi IL-6 : Negatif / Lemah 1+ / Moderat 2+ / Kuat 3+
- Ekspresi TNF- α : Negatif / Lemah 1+ / Moderat 2+ / Kuat 3+

Pemeriksaan ELISA humor akuos untuk konsentrasi IL-6 dan TNF- α

- Konsentrasi IL-6 : _____
- Konsentrasi TNF- α : _____

Lampiran 4 : Data Induk Penelitian

NO	Umur	Jenis Kelamin	Riwayat DM	Durasi	GDS terakhir	HbA1C	usia Mata yg Oper	atarak berdasarkan	ting Retinopati Di	amerika IHC	amerika IHC TN	eriksaan ELISA	Pemeriksaan ELISA TNF-A
1	43	perempuan	Ya	<5 TAHUN	135	5.9	20/80	2	R NON HIGH RI	0	0	48.14498	16.44897
2	67	perempuan	Ya	5-10 TAHUN	194	8.3	20/200	2	NO DR	0	0	18.14377	15.70619
3	65	perempuan	Ya	5-10 TAHUN	190	10.2	1/60	4	MILD NPDR	0	2	18.10854	13.96818
4	78	laki-laki	Ya	5-10 TAHUN	162	6.7	20/100	3	NO DR	3	0	16.27794	14.85277
5	63	laki-laki	YA	5-10 TAHUN	183	7.6	3/60	3	NO DR	3	0	11.71052	17.63263
6	56	perempuan	YA	5-10 TAHUN	234	9.1	3/60	3	MODERATE NPDR	0	0	12.16408	14.39027
7	52	perempuan	Ya	<5 TAHUN	374	7.2	20/200	2	NO DR	1	0	11.32018	14.69836
8	56	laki-laki	Ya	<5 TAHUN	116	9.8	20/70	3	MODERATE NPDR	1	0	10.73546	19.83711
9	52	perempuan	Ya	<5 TAHUN	347	7.2	20/200	3	NO DR	3	0	9.288115	15.82312
10	45	laki-laki	Ya	<5 TAHUN	227	11.9	0.5/60	4	MILD NPDR	0	0	16.78343	14.77554
11	56	perempuan	Ya	5-10 TAHUN	274	11.9	20/100	3	PDR HIGH RISK	0	2	16.60473	14.39027
12	58	laki-laki	Ya	5-10 TAHUN	225	6.8	20/70	2	MILD NPDR	3	0	6.407317	13.16732
13	57	perempuan	Ya	5-10 TAHUN	250	9.8	0.5/60	2	PDR HIGH RISK	3	0	34.34275	15.78412
14	43	perempuan	Ya	5-10 TAHUN	134	10	1/60	3	PDR HIGH RISK	3	2	68.88215	16.13557
15	66	perempuan	YA	5-10 TAHUN	127	11.6	1/300	5	PDR HIGH RISK	3	2	29.3528	16.96026
16	58	perempuan	Ya	5-10 TAHUN	138	8.5	3/60	3	R NON HIGH RI	0	0	38.70519	12.67481
17	60	laki-laki	Ya	5-10 TAHUN	104	11.5	1/60	3	NO DR	0	0	14.64532	15.2398
18	48	perempuan	Ya	<5 TAHUN	298	9.4	0.5/60	5	NO DR	3	0	2.220107	15.58939
19	69	laki-laki	Ya	<5 TAHUN	235	10.7	20/200	3	MILD NPDR	1	0	4.780364	13.39548
20	80	perempuan	Ya	5-10 TAHUN	121	6.5	20/70	4	SEVERE NPDR	3	0	6.509283	17.39484
21	67	perempuan	Ya	5-10 TAHUN	84	5.2	20/400	3	NO DR	3	0	9.858663	14.15982
22	50	perempuan	Ya	<5 TAHUN	140	8.3	1/60	3	NO DR	3	0	7.553995	15.16228
23	67	perempuan	Ya	<5 TAHUN	143	6.8	20/400	3	NO DR	2	0	16.94253	13.58601
24	58	perempuan	Ya	5-10 TAHUN	138	8.5	20/80	3	R NON HIGH RI	3	0	22.82064	14.00648
25	41	laki-laki	Ya	>10 TAHUN	152	8.1	20/400	3	NO DR	0	0	22.51097	15.08481
26	55	perempuan	Ya	5-10 TAHUN	148	8.2	1/60	3	MILD NPDR	1	0	14.72314	15.97923
27	50	laki-laki	Ya	5-10 TAHUN	104	11.5	20/200	2	MILD NPDR	3	2	12.72943	15.31738
28	59	perempuan	ya	<5 TAHUN	261	10.9	2/60	4	R NON HIGH RI	3	0	13.87047	18.18954
29	60	perempuan	ya	5-10 TAHUN	160	6.2	20/100	2	NO DR	3	0	8.013555	17.27614
30	43	perempuan	ya	5-10 TAHUN	116	10	2/60	3	PDR HIGH RISK	3	0	30.96696	13.77691
31	73	perempuan	ya	5-10 TAHUN	284	8.7	1/60	3	NO DR	3	1	9.434995	15.47273
32	53	laki-laki	ya	<5 TAHUN	216	8.2	3/60	3	NO DR	2	0	13.03969	17.2366
33	58	laki-laki	Ya	<5 TAHUN	203	5.3	20/200	2	NO DR	0	0	10.80545	16.29216
34	61	laki-laki	Tidak	tidak	120	-	20/100	3	-	3	2	6.464934	16.44897
35	75	laki-laki	Tidak	tidak	98	-	20/200	4	-	0	0	13.65367	17.59296
36	61	laki-laki	Tidak	tidak	89	-	20/400	3	-	3	1	4.559333	17.51367
37	71	perempuan	Tidak	tidak	97	-	NLP	5	-	1	0	4.015972	22.87349
38	62	perempuan	Tidak	tidak	120	-	20/200	3	-	0	0	10.42831	16.60603
39	65	perempuan	Tidak	tidak	100	-	20/100	3	-	1	0	2.771616	15.20103
40	40	laki-laki	Tidak	tidak	83	-	1/300	4	-	0	0	6.296631	15.39503
41	59	perempuan	Tidak	tidak	91	-	1/60	4	-	2	0	9.150642	16.33134
42	60	perempuan	Tidak	tidak	138	-	3/60	3	-	0	0	9.059115	17.27614
43	64	perempuan	Tidak	tidak	152	-	20/200	3	-	3	0	3.99449	21.01743
44	49	perempuan	Tidak	tidak	94	-	1/300	4	-	0	0	9.499333	9.761774
45	56	perempuan	Tidak	tidak	112	-	20/100	2	-	1	2	5.425373	23.91754
46	65	laki-laki	Tidak	tidak	104	-	20/400	3	-	0	0	13.7837	14.96872
47	48	perempuan	Tidak	tidak	84	-	20/100	2	-	2	2	10.53524	14.46721
48	60	perempuan	Tidak	tidak	106	-	0.5/60	4	-	0	0	9.715675	16.25299
49	82	perempuan	Tidak	tidak	73	-	20/80	2	-	0	0	13.22634	15.5116
50	69	perempuan	Tidak	tidak	84	-	0.5/60	3	-	0	0	5.798228	17.03914

51	48	perempuan	Tidak	tidak	107	-	20/70	3	-	0	0	6.758086	21.34521
52	75	laki-laki	Tidak	tidak	98	-	20/100	2	-	0	0	7.774448	19.99918
53	101	laki-laki	Tidak	tidak	85	-	1/300	5	-	0	0	8.339476	14.15982
54	59	laki-laki	Tidak	tidak	118	-	2/60	3	-	0	0	9.761774	13.24332
55	65	laki-laki	Tidak	tidak	110	-	20/400	3	-	0	0	7.101437	16.1747
56	59	laki-laki	Tidak	tidak	186	-	20/400	3	-	0	0	8.072308	14.08312
57	50	laki-laki	Tidak	tidak	88	-	0.5/60	4	-	1	0	21.28079	22.54134
58	79	laki-laki	Tidak	tidak	117	-	20/200	2	-	0	0	15.15719	27.66585
59	68	perempuan	Tidak	tidak	86	-	20/70	2	-	0	0	10.15924	13.70051
60	37	laki-laki	Tidak	tidak	123	-	20/400	2	-	0	0	10.27975	14.46721
61	65	perempuan	Tidak	tidak	114	-	20/300	3	-	0	0	11.85202	13.58601
62	53	perempuan	Tidak	tidak	125	-	3/60	2	-	0	0	15.25989	14.81414
63	55	laki-laki	Tidak	tidak	102	-	20/100	2	-	0	0	11.74823	13.9299
64	54	laki-laki	Tidak	tidak	98	-	0.5/60	3	-	0	0	8.271471	19.71572
65	73	laki-laki	Tidak	tidak	104	-	20/70	2	-	0	0	9.988014	17.47404
66	65	laki-laki	Tidak	tidak	91	-	0.5/60	3	-	0	0	10.12682	13.09139